Objective: To assess risk factors for paravalvular leak (PVL) after transcatheter aortic valve implantation in a large single-center cohort, including measurement of aortic valve calcification using a reproducible method. 3 , with no significant differences among the 4 prosthesis groups. None of the patients had severe PVL. The overall incidence of mild-to-moderate PVL was 15.8% (95% confidence interval [CI], 12.8%-19.1%). On multivariate logistic regression, device landing zone calcification (P ¼ .00006; odds ratio for an increase of 100 mm 3 , 1.08; 95% CI, 1.04-1.13) and use of the CoreValve (P ¼ .0028; odds ratio, 4.1; 95% CI, 1.6-10 with SapienXT as reference) prosthesis were found to be associated with mild or greater PVL. In contrast, degree of oversizing (P ¼ .002; odds ratio, 0.97; 95% CI, 0.95-0.99), and use of Sapien3 (P ¼ .00005; odds ratio, 0.23; 95% CI, 0.11-0.47 with SapienXT as reference) were associated with a lower incidence of mild or greater PVL.
Results: Overall, 539 patients were included in the study who had experience with 4 3 , with no significant differences among the 4 prosthesis groups. None of the patients had severe PVL. The overall incidence of mild-to-moderate PVL was 15.8% (95% confidence interval [CI], 12.8%-19.1%). On multivariate logistic regression, device landing zone calcification (P ¼ .00006; odds ratio for an increase of 100 mm 3 , 1.08; 95% CI, 1.04-1.13) and use of the CoreValve (P ¼ .0028; odds ratio, 4.1; 95% CI, 1.6-10 with SapienXT as reference) prosthesis were found to be associated with mild or greater PVL. In contrast, degree of oversizing (P ¼ .002; odds ratio, 0.97; 95% CI, 0.95-0.99), and use of Sapien3 (P ¼ .00005; odds ratio, 0.23; 95% CI, 0.11-0.47 with SapienXT as reference) were associated with a lower incidence of mild or greater PVL.
Conclusions: Aortic calcification volume in the device landing zone is associated with residual PVL after transcatheter aortic valve implantation. When taking calcification into account, the balloon-expandable prosthesis Sapien3 seems to be associated with a lower incidence of PVL. (J Thorac Cardiovasc Surg 2019;157:1406-15)
Implantation of a CoreValve prosthesis (Medtronic, Minnepolis, Minn) in a woman with an extremely calcified aortic valve.
Central Message
Device landing zone calcium volume is associated with paravalvular leak (PVL). A calcium volume with a cutoff of 1079 mm 3 identifies patients with mild or greater PVL. The risk of PVL increases by 8% every 100 mm 3 of calcium volume.
Perspective
Aortic valve calcification plays a role in the onset of paravalvular leak (PVL) after transcatheter aortic valve implantation (TAVI). However, most available studies suffer from limited sample size or biased determination of aortic calcification. We aimed at assessing risk factors for PVL after TAVI in a large single-center cohort, including clinical and procedural factors along with calcium volume measurement using a reproducible method.
See Editorial Commentary page 1416.
Transcatheter aortic valve implantation (TAVI) has emerged as a new standard for percutaneous treatment of severe aortic valve stenosis in patients at intermediate and high surgical risk or who are inoperable. 1 However, its wide application is yet limited by the occurrence of postoperative paravalvular leak (PVL), which portends increased mortality during follow-up. 2 Aortic valve calcification has been found to be associated with PVL, [3] [4] [5] [6] but results from the available literature have been obtained in studies with limited sample sizes 7 or influenced by several bias, including methods for calcium determination 8 or center effect in multicenter studies. 9 The aim of this study was to assess risk factors for PVL after TAVI in a large single-center cohort, including aortic valve calcification as measured by contrast-enhanced multidetector computed tomography (MDCT).
METHODS

Study Population
We retrospectively analyzed our center experience with TAVI procedures between July 2009 and October 2016. All patients who underwent TAVI for symptomatic severe stenosis of the native aortic valve were included in the study. Severe aortic stenosis was defined in accordance with international guidelines. 1 Exclusion criteria were bicuspid aortic valve, pure aortic regurgitation, and aborted procedures because of annulus diameter >30 mm. Overall, 659 patients were eligible for the study. However, 108 patients had not had an MDCT scan (this was not yet a standard for the first patients or the scan was performed 5 years previously and MDCT images were not retrievable from our Picture Archiving and Communication System), 4 patients had no preoperative contrast-enhanced MDCT because of severe renal impairment, 3 patients did not have electrocardiography (ECG)-triggered MDCT scans and were unsuitable for analysis, and 5 patients were treated with an experimental second-generation prosthesis. Thus, a total of 539 patients were evaluable (Figure 1 ). Clinical and operative data were prospectively collected in our institutional database. The following intraoperative outcomes were recorded based on the Valve Academic Research Consortium-2 recommendations 10 : unplanned cardiopulmonary bypass, conversion to surgery, coronary obstruction, prosthesis valve malpositioning, second prosthesis implantation, and intraoperative percutaneous coronary intervention (PCI). All patients provided written informed consent for the use of their data anonymously, and the study was approved by our institutional review board (approval No. IRB-2017-006). The study protocol conforms to the ethical guidelines in the Declaration of Helsinki.
The Heart Team
According to international guidelines, 1 indication for TAVI is discussed within a Heart Team, composed of at least a cardiologist and a cardiac surgeon evaluating patients with severe aortic valve stenosis, including those referred to our center from peripheral hospitals, private practices, or our emergency department. All patients with frailty factors who were judged inoperable or at high surgical risk (as defined by logistic European system for cardiac operative risk evaluation score>20%) were considered eligible for TAVI.
MDCT Angiography and Calcium Quantification
All patients underwent contrast-enhanced ECG-gated MDCT (330 ms rotation, helical mode, 60%-70% gating, 0.6 3 64 mm collimation, 50-100 mL intravenous contrast agent [Solutrast 370, Bracco Imaging Deutschland GmbH, Konstanz, Germany] at 4 mL/sec) for assessment of aortic root anatomy (suitability for TAVI) and the femoral axis (suitably for transfemoral [TF] approach). In our center, all MDCT studies were performed with a 64-slice Somatom Definition AS (Siemens Healthcare GmbH, Erlangen, Germany) and were analyzed by the Heart Team using 3mensio Structural Heart software (version 7.0 SP1, Medical Imaging BV, Bilthoven, the Netherlands), which allowed assessment of the basal plane (aortic annulus), defined as the virtual plane crossing the nadir of each aortic cusp in diastole (Video 1).
Calcium volume in the aortic valve was retrospectively measured using 3mensio (Video 1). After identification of the basal plane, the lower coronary ostium was determined and the region of interest (ROI) was set before the origin of the coronary vessel. Figure 2 and Video 1). The threshold for calcium detection was set to 2 different cutoff values depending on the average HU of blood in the ascending aorta. For values between 130 and 300 HU, a threshold of 500 HU was chosen, in line with previous studies. 3, 9 In contrast, for values between 300 and 600 HU (46 patients), an empiric threshold of 800 HU was chosen. Measurements of calcium volume were performed by a cardiac surgeon experienced in TAVI and trained in the use of 3mensio (FP). Interobserver variability was tested for the first 20 cases by a second cardiac surgeon (SP) and was 4.8%.
The degree of over-or undersizing was calculated as prosthesis valve area (provided by the manufacturer)/MDCT annular area. Prosthesis valve area was derived according to the geometrical rule:
, where d is the labeled prosthesis size. Aortic annulus eccentricity index was calculated as 1 -(minimal diameter/maximal diameter) based on MDCT annular measurements.
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PVL Quantification
PVL was quantified by intraoperative transesophageal echocardiography (TEE) performed by a dedicated cardiac anesthesiologist under supervision of a cardiologist. To obtain maximum accuracy, a multiwindow and multiparametric (qualitative and quantitative) approach was applied to assess PVL severity. 12 The PVL was categorized as 0 ¼ none, 0.5 ¼ trace, 1 ¼ mild, 1.5 ¼ mild to moderate, 2 ¼ moderate, 2.5 ¼ moderate to severe, and 3 ¼ severe.
Procedure TF-TAVI was preferred as first choice in all patients without severe peripheral artery disease and with suitable femoral axis. Alternatively, the transapical (TA-TAVI) access was used. All procedures were conducted in a hybrid operating room under fluoroscopic control (Artis Zeego System; Siemens AG), general anesthesia, periprocedural TEE, and a cardiac perfusionist with ready-to-use cardiopulmonary bypass on site. All implants were performed by a multidisciplinary team composed of at least a cardiologist (procedure leader in case of TF-TAVI) and a cardiac surgeon (procedure leader in case of TA-TAVI). Four different prostheses are routinely implanted in our center: SapienXT and Sapien3 (Edwards Lifesciences, Irvine, Calif), CoreValve/EvolutR (Medtronic, Minneapolis, Minn), and Acurate TA/NeoTF (Symetis SA, Ecublens, Switzerland). Selection of prosthesis type is agreed preoperatively with the cardiologist and cardiac surgeon on the basis of several parameters, including need for elective PCI after TAVI, annulus dimension, and distance from the aortic annulus to the coronary ostia. Definitive selection of prosthesis size is usually agreed intraoperatively by the Heart Team after evaluation of MDCT (annular perimeter-derived dimensions), TEE, and angiographic parameters (eg, contrast reflux during valvuloplasty and balloon sizing).
Statistical Analysis
Data consistency was checked and data were screened for outliers and normality by using quantile plots. Continuous variables were also tested for normality by using Kolmogrov-Smirnov test. Categorical variables are expressed as frequencies and percentages and continuous variables as mean AE standard deviation or median and interquartile range. To assess the performance of different prosthetic valves in different calcification patterns, the study population was divided into 4 groups according to the implanted prosthesis. Differences between groups were determined by analysis of variance testing with Bonferroni correction and Kruskal-Wallis test. Cross tabulation tables with Kruskal-Wallis test for singly ordered variables. Potential risk factors for the occurrence of mild or greater PVL, including computed tomography, baseline, and operative parameters of patients were entered in the univariate and multivariate logistic regression models. The dependent variable of the logistic model was the occurrence of PVL. A univariate analysis was first performed. Variables with P < .2 were included in a multivariable logistic model regression analysis using stepwise selection algorithm (hierarchical forward with switching) to identify the predictors of PVL. Odds ratios with corresponding 95% confidence intervals (CIs) were computed in each model. The discrimination achieved was assessed with the C statistic, which is equivalent to the area under the receiver operating characteristic curve. A generalized linear model for PVL location was built to analyze the relation between calcium distribution across the aortic cusps (based on the multinomial distribution for PVL location).
Clinical, procedural, ECG, and preoperative MDCT variables were entered into univariate analysis. A receiver operating characteristic (ROC) curve was calculated from the DLZ, allowing assessment of cutoff values defining mild or greater PVL. All reported tests were 2-sided, and P values < .05 were considered as statistically significant. All statistical analyses in this report were performed using NCSS (NCSS 10; NCSS, LLC, Kaysville, Utah), Statistica version 13 (StatSoft, Tulsa, Okla), and PASW 23 (version 21.0 for Windows; IBM-SPSS, Armonk, NY).
RESULTS
Patient clinical and procedural characteristics are shown in Table 1 , and MDCT measurements, including calcium volume are listed in Table 2 , according to the implanted prosthesis. The TF access route was most frequently used for TAVI (67% of cases). All groups had a mean logistic European system for cardiac operative risk evaluation score >20%. Calcium volume in the DLZ varied from a minimum of 17.5 mm 3 to a maximum of 4523 mm 3 .
Significant differences among the prosthesis groups were observed in New York Heart Association class, size of prosthesis used, valve area, annulus perimeter, distance between the coronary ostia and annuli, and oversizing. Calcium volume in the DLZ and in the diverse subsectors did not significantly differ among groups. Figure 3 , A, and Table E1 show the incidence of PVL by prosthesis group. Overall, 199 patients (36.9%) had an intraoperative leak (from trace to moderate). No patient presented severe or moderate to severe PVL. Patients implanted with the Sapien3 valve had the lowest incidence and degree of PVL. The distribution of calcium volume in the DLZ for patients with none, trace, mild, and moderate PVL are showed in Figure E1 according to valve prosthesis. Logistic regression model (C statistic, 0.809; 95% CI, 0.771-0.843) (Table 3) , based on preoperative variables of Tables 1 and 2 , identified DLZ calcification and use of CoreValve/EvolutR prosthesis as associated with mild or greater PVL. On the other hand, degree of oversizing and use of Sapien3 were associated with a lower incidence of mild or greater PVL. The discriminating power of DLZ calcification was evaluated by C statistic and ROC curve analysis. The area under the ROC curve ( Figure E2 ) was 0.66 (95% CI, 0.617-0.699; P ¼ .0001) for mild or greater PVL. The ROC analysis identified the cutoff value of 1079 mm 3 (sensitivity 53%; specificity 75%) for DLZ calcification, above which a significantly increased risk of mild or greater PVL was observed. Differences in PVL incidence for DLZ higher or lower than 1079 mm 3 are shown in Figure 3 , B, for each prosthesis group. A DLZ calcium volume >1079 mm 3 was associated with a significantly higher incidence of mild or greater PVL in all prosthesis groups (P <.05).
Among the 199 patients with PVL, data on annular leak location were missing in 33. In the remaining 166 patients, the lowest incidence of PVL was detected in the RCC (5.4%), which also had less calcium volume in the LVOT. PVL was located more frequently in the LCC (59.6%), followed by the NCC (26.5%). In the remaining 8.4% of cases, it occurred at the commissure level (LCC/NCC, 5.4%; NCC/RCC, 0.6%; and RCC/LCC, 2.4%). On generalized linear model (multinomial model) no significant relations were found between PVL location and calcium distributions across the aortic cusps.
Other Intraoperative Complications and Outcome
Prosthesis migration or malpositioning occurred in 6 cases (3 SapienXT 9.7%). Three patients underwent emergent surgical aortic valve replacement following explantation of the TAVI device. Three patients underwent emergency valve-invalve implantation with good results in 2 and conversion to surgical aortic valve replacement in 1. All 6 patients survived the procedure. Annular rupture occurred in 2 patients (DLZ calcium of 2828 and 613 mm 3 , respectively, with intraprocedure death in 1 patient, and discharge to home in the other). Coronary obstruction as isolated complication (unrelated to prosthesis migration) occurred in 2 patients (DLZ calcium, 1044 and 156 mm 3 [Sapien XT]), requiring emergency PCI in 1 patient and coronary artery bypass graft in the other. Overall, immediate and 30-day mortality was 0.93% (n ¼ 5) and 5.38% (n ¼ 29), respectively.
DISCUSSION
Our study evaluated postimplant PVL occurrence and grade using a multimodality approach that included measurement of aortic valve calcification. On the basis of our results, DLZ calcification plays a key role in PVL occurrence after TAVI, and routine determination of calcium volume with a quantitative and reproducible measurement may provide additional useful information for planning interventions. In presence of extensive DLZ calcifications and increased risk of PVL, the procedural strategy should be modified accordingly, trying to reduce the burden of other contributing but controllable factors (eg, oversizing and choice of prosthesis), and CoreValve prosthesis is more vulnerable and performs less efficiently in the presence of severe calcification.
The use of MDCT has become routine for transcatheter heart valve sizing and procedure planning. 1 Given the availability of improved imaging software and the widespread use of TAVI, we adopted a new approach to extract the most information from MDCT and achieve the best possible outcome.
The presence of even mild residual PVL in high-risk patients was found to be associated with a significantly worse survival compared with that of patients who did not exhibit such complication, up to 5-year follow-up. 2 In intermediate-risk patients, this tendency was also observed for moderate or greater PVL. 13 The incidence of mild or greater PVL varies across studies, ranging from 44% to 77%, with moderate or greater PVL ranging from 3.1% to 21.6%. 14, 15 In our study, greater than mild PVL was observed in 15.76% of patients, with 1.4% experiencing moderate PVL and none severe PVL, which is significantly lower than the incidence reported in the literature. In our opinion, 2 factors may account for this , where the latter is a further development of the former and was used in the majority of our study patients, seems to confirm that the improvements introduced in the newer generation valves (eg, annular skirt) have fulfilled the predetermined purpose of reducing PVL occurrence, as also demonstrated in the SOURCE-3 Registry. 14 Second, the higher use of balloon postdilation (34.13%). This is the result of our team's choice of low tolerance of moderate or greater PVL, which proved to be safe, with only 1 case of annular rupture among patients who underwent balloon postdilation.
Our study aimed at identifying a practical method for preprocedural calcification assessment. The critical value above which all prosthesis models were vulnerable seems to be >1000 mm 3 (reference was PVL of mild degree or greater). Despite the sensitivity and specificity of this threshold not being optimal, this finding is consistent with previous research. 3 In every case, the low incidence of other intraoperative complications, apparently unrelated to the degree of calcification, confirms that TAVI remains a safe procedure.
To the best of our knowledge, this study is the largest to assess calcium volume in patients undergoing TAVI. Studies based on reproducible and quantitative methods (or dedicated software) for quantification of aortic valve calcification have so far been scant, with limited sample size or several potential biases.
In 123 patients implanted with a Sapien/SapienXT valve (23 and 26 mm) prosthesis, Jilaihawi and colleagues 4 tested the reliability of contrast-enhanced MDCT for calcium quantification at multiple thresholds for detection compared with the traditional Agatston scoring used for noncontrast MDCT scans. On multivariate analysis, prosthesis undersizing and presence of LVOT calcium were predictors of PVL.
In a retrospective study, Koh and colleagues 7 evaluated 56 patients who underwent TAVI with TA or transaortic delivery of an Sapien valve (no longer commercially available). Calcium volume was significantly higher in patients with PVL, but no correlation was found with PVL grade. These findings were not supported by multivariate analysis.
Seiffert and colleagues 9 evaluated the influence of calcium volume on PVL using a similar method to ours and reported comparable median calcium volumes (619 mm 3 in the aortic valve and 11 mm 3 in the LVOT). DLZ calcium, particularly if located in the LVOT, was predictive of PVL. In the study by Seiffert and colleagues 9 a higher incidence of PVL was observed. Because this was a 2-center study, 1 possible reason accounting for this finding is a center effect, which was also identified at linear regression analysis. Another aspect that deserves consideration is the low number of implants of 23-mm valves performed in their patients. In addition, in their study, only next-generation transcatheter aortic prostheses for TA access (eg, JenaValve [JenaValve Technology GmbH, Munich, Germany], Engager [Medtronic]) were used, equipped with a peculiar implant system. Further, no balloon-expandable Sapien3 prosthesis was used in their study, which on the contrary accounts for 38% of the prostheses used in our study and implanted via TF access in 75% of cases. Similar to the experience of Seiffert and colleagues 9 the CoreValve prosthesis was associated with a higher incidence of PVL. Although no small-sized CoreValve prostheses (23 mm) were used in our population, multivariate analysis has ruled out annular size as a risk factor for PVL. This means that the high incidence of PVL in this group cannot be explained solely by its use in large aortic annuli. Additionally, the CoreValve group had the highest degree of oversizing, which was found to be a protective factor for subsequent PVL. An explanation may lie in the peculiar radial forces of the CoreValve nitinol stent. Figure 4 shows how a severe calcification, despite 34% oversizing, can result in a noncorrectable PVL, even after postdilatation, in a CoreValve prosthesis. It should be noted that only intraoperative TEE was evaluated because it is highly accurate in discriminating PVL from central regurgitation and our study was focused solely on the acute outcome. However, it has been demonstrated that incidence and severity of PVL after CoreValve implantation tend to diminish over time, showing a significant reduction after 1 year. 16 Incidence of PVL at discharge (assessed through transthoracic echocardiography) in our series is showed in Figure E3 and Table E1 . Bearing in mind the inferiority of transthoracic echocardiography with respect to the TEE, we did not observe any reduction in the incidence of mild or greater PVL.
Localization of PVL
Although our analysis confirmed that aortic calcification is crucial in determining postimplant PVL, less clear conclusions can be drawn regarding PVL location. A very low incidence of PVL was observed in the RCC. One possible explanation for this finding is that the RCC is positioned above the interventricular septum, which is probably a more stable cardiac structure allowing better sealing compared with the left and right fibrous trigone with which the LCC and NCC, respectively, are in direct continuity. However, the fact that PVL was found to be most frequently located in the LCC despite higher calcium volume along the NCC, remains unexplained. This may be due to confounding factors (eg, radial force distribution of the different stent designs) that, along with calcification, may contribute to determine the location of PVL, or a bias in reporting localization of PVL. Given that the valve systems used in our study do not provide an anatomic orientation of the prosthesis into the aortic annulus, the exact recognition of the native cusps is difficult after implantation. Fluoroscopy provides only a 2-dimensional projection, and the use of intraoperative 3-dimensional TEE is not routine practice in our institution. Notwithstanding this, future prospective studies using intraoperative 3-dimensional imaging are required to address the issue of PVL localization.
Study Limitations
Several limitations should be acknowledged in this study. First, the method used for assessing aortic calcification. Previous studies investigated the reliability of contrast-enhanced MDCT and different thresholds with nonenhanced MDCT. 4 Unfortunately, the results of contrast-enhanced MDCT remain strongly dependent on the selected HU threshold. Indeed, the choice of testing blood HU in the ascending aorta was intended to avoid relevant mistakes deriving from the indiscriminate use of the same threshold for all study patients. The selected threshold of 500 HU (and 800 HU in some cases) is arbitrary and needs to be validated, although adopted in previous similar studies. 3, 4, 9 Second, differences in prosthesis groups, where a greater expertise in balloonexpandable prostheses was likely. Third, extended calcifications may be hiding undetected bicuspid aortic valves that could be account as confounding factors. 17 Fourth, the retrospective nature of our study, which calls for the need of randomized prospective studies to validate our findings. Until then, suggesting a specific prosthesis for a particular calcification pattern would be imprudent. Moreover, the importance of other perioperative complications (eg, vascular complications, stroke, and need for permanent pacemaker implantation) should not be underestimated and is currently the subject of dedicated studies from our team.
CONCLUSIONS
Aortic calcification volume in the DLZ is associated with residual PVL after TAVI. When taking calcification into account, the balloon-expandable prosthesis Sapien3 seems to be associated with a lower incidence of PVL. 
